Emil Kakkis
Emil Kakkis is a renowned medical doctor and biochemist known for his significant contributions to the field of rare diseases and orphan drugs.
Pronunciation
Emil Kakkis: /ˈiːmɪl ˈkækɪs/
Etymology
The name Emil is of Latin origin, derived from the word "Aemilius," meaning "rival." The surname Kakkis is of Greek origin.
Career
Emil Kakkis began his career as a medical geneticist, specializing in the treatment of metabolic diseases. He later transitioned into the pharmaceutical industry, where he developed a passion for creating treatments for rare diseases. His work led to the development of two significant FDA-approved drugs, Aldurazyme and Naglazyme, which treat Mucopolysaccharidosis I (MPS I) and Mucopolysaccharidosis VI (MPS VI) respectively.
In 2010, Kakkis founded the EveryLife Foundation for Rare Diseases, a non-profit organization dedicated to advancing the development of treatment and diagnostic opportunities for rare disease patients through science-driven public policy.
Related Terms
- Medical Genetics
- Metabolic Diseases
- Rare Diseases
- Orphan Drugs
- Mucopolysaccharidosis I (MPS I)
- Mucopolysaccharidosis VI (MPS VI)
- EveryLife Foundation for Rare Diseases
External links
- Medical encyclopedia article on Emil Kakkis
- Wikipedia's article - Emil Kakkis
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski